Comorbidities and co-medications in populations with and without chronic hepatitis C virus infection in Japan between 2015 and 2016

BACKGROUND: Direct-acting anti-viral agents have improved the treatment of chronic hepatitis C virus (HCV) infection, but this treatment is challenging for patients using co-medications because of potential drug–drug interactions. This study aimed to examine the comorbidities and co-medications of J...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruzicka, Daniel J., Tetsuka, Jumpei, Fujimoto, Go, Kanto, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968711/
https://www.ncbi.nlm.nih.gov/pubmed/29793436
http://dx.doi.org/10.1186/s12879-018-3148-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968711/
https://www.ncbi.nlm.nih.gov/pubmed/29793436
http://dx.doi.org/10.1186/s12879-018-3148-z

Ejemplares similares